Human Plasma-Derived Exosomes: A Promising Carrier System for the Delivery of Hydroxyurea to Combat Breast Cancer

IF 3.4 4区医学 Q2 PHARMACOLOGY & PHARMACY AAPS PharmSciTech Pub Date : 2025-01-22 DOI:10.1208/s12249-024-03028-w

Wajeeha Khalid, Afeefa Aslam, Nadeem Ahmed, Muhammad Sarfraz, Jawad Akbar Khan, Sabeeh Mohsin, Muhammad Shahid Riaz Rajoka, Imran Nazir, Muhammad Imran Amirzada

{"title":"Human Plasma-Derived Exosomes: A Promising Carrier System for the Delivery of Hydroxyurea to Combat Breast Cancer","authors":"Wajeeha Khalid, Afeefa Aslam, Nadeem Ahmed, Muhammad Sarfraz, Jawad Akbar Khan, Sabeeh Mohsin, Muhammad Shahid Riaz Rajoka, Imran Nazir, Muhammad Imran Amirzada","doi":"10.1208/s12249-024-03028-w","DOIUrl":null,"url":null,"abstract":"<div><p>The aim of the present study was to investigate the potential of human plasma derived exosomes for the delivery of hydroxyurea to enhance its therapeutic efficacy in breast cancer. Plasma derived exosomes were isolated using differential centrifugation along with ultrafiltration method. Hydroxyurea was encapsulated in exosomes using a freeze–thaw method. The exosomes and Exo-HU were characterized for their size distribution, drug entrapment efficiency, <i>in-vitro</i> drug release profile, morphological analysis and cytotoxic effects on MCF-7 cell line. The results showed a mean size of 178.8 nm and a zeta potential of -18.3 mV, indicating good stability and 70% encapsulation effectiveness for HU. Exo-HU produced sustained drug release action with a considerable percentage released within 72 h. The morphological analysis indicated that the plasma derived exosomes were spherical, and cup shaped. In cytotoxicity studies on MCF-7 cells, Exo-HU has reduced cell viability compared to HU and blank exosomes. Findings of this study showed that human plasma-derived exosomes have been considered as effective delivery vehicle for hydroxyurea, potentially improving breast cancer treatment outcomes.</p><h3>Graphical Abstract</h3>\n<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":6925,"journal":{"name":"AAPS PharmSciTech","volume":"26 1","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AAPS PharmSciTech","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1208/s12249-024-03028-w","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

The aim of the present study was to investigate the potential of human plasma derived exosomes for the delivery of hydroxyurea to enhance its therapeutic efficacy in breast cancer. Plasma derived exosomes were isolated using differential centrifugation along with ultrafiltration method. Hydroxyurea was encapsulated in exosomes using a freeze–thaw method. The exosomes and Exo-HU were characterized for their size distribution, drug entrapment efficiency, in-vitro drug release profile, morphological analysis and cytotoxic effects on MCF-7 cell line. The results showed a mean size of 178.8 nm and a zeta potential of -18.3 mV, indicating good stability and 70% encapsulation effectiveness for HU. Exo-HU produced sustained drug release action with a considerable percentage released within 72 h. The morphological analysis indicated that the plasma derived exosomes were spherical, and cup shaped. In cytotoxicity studies on MCF-7 cells, Exo-HU has reduced cell viability compared to HU and blank exosomes. Findings of this study showed that human plasma-derived exosomes have been considered as effective delivery vehicle for hydroxyurea, potentially improving breast cancer treatment outcomes.

Graphical Abstract

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

人血浆源性外泌体：一种有前途的羟脲抗乳腺癌载体系统

本研究的目的是探讨人血浆源性外泌体输送羟基脲的潜力，以提高其对乳腺癌的治疗效果。采用差速离心和超滤法分离血浆源性外泌体。用冻融法将羟基脲包封在外泌体中。研究了外泌体和Exo-HU的大小分布、药物包裹效率、体外药物释放谱、形态分析和对MCF-7细胞系的细胞毒性作用。结果表明，平均粒径为178.8 nm， zeta电位为-18.3 mV，具有良好的稳定性和70%的包封率。Exo-HU具有持续的药物释放作用，在72 h内释放的比例相当大。形态学分析表明血浆源性外泌体呈球形和杯状。在MCF-7细胞的细胞毒性研究中，与HU和空白外泌体相比，Exo-HU降低了细胞活力。本研究结果表明，人血浆来源的外泌体被认为是羟基脲的有效递送载体，可能改善乳腺癌的治疗效果。图形抽象

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

AAPS PharmSciTech 医学-药学

CiteScore

6.80

自引率

3.00%

发文量

264

审稿时长

2.4 months

期刊介绍： AAPS PharmSciTech is a peer-reviewed, online-only journal committed to serving those pharmaceutical scientists and engineers interested in the research, development, and evaluation of pharmaceutical dosage forms and delivery systems, including drugs derived from biotechnology and the manufacturing science pertaining to the commercialization of such dosage forms. Because of its electronic nature, AAPS PharmSciTech aspires to utilize evolving electronic technology to enable faster and diverse mechanisms of information delivery to its readership. Submission of uninvited expert reviews and research articles are welcomed.